Previous 10 | Next 10 |
Repare Therapeutics ( RPTX ) has filed a preliminary prospectus for its IPO of 10M common shares at $18 - 20 per share. More news on: Repare Therapeutics, IDEAYA Biosciences, Inc., GlaxoSmithKline plc, Healthcare stocks news, IPO News, , Read more ...
SOUTH SAN FRANCISCO, Calif. , June 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering. In addition, IDEAYA intends to grant the underwriters ...
Gainers: ClearSign Technologies (NASDAQ: CLIR ) +171% . More news on: ClearSign Technologies Corporation, Urban One, Inc., Mid-Con Energy Partners, LP, Stocks on the move, Read more ...
Mid-Con Energy Partners (NASDAQ: MCEP ) +154% on Q1 results . More news on: Mid-Con Energy Partners, LP, IDEAYA Biosciences, Inc., iQIYI, Inc., Stocks on the move, , Read more ...
IDEAYA Biosciences (NASDAQ: IDYA ) is up 36% premarket on the heels of announcing a strategic partnership with GlaxoSmithKline plc (NYSE: GSK ) in Synthetic Lethality , an emerging field in Oncology. More news on: IDEAYA Biosciences, Inc., GlaxoSmithKline plc, Healthcare stock...
SOUTH SAN FRANCISCO, Calif. and LONDON , June 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethality, an emerging field in Oncology. The strategic partnership includ...
SOUTH SAN FRANCISCO, Calif. , June 11, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. ...
IDEAYA Biosciences (NASDAQ: IDYA ) has selected development candidate IDE397 for its Methionine adenosyltransferase 2a (MAT2A) Synthetic Lethality program. More news on: IDEAYA Biosciences, Inc., Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif. , June 8, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, announc...
Gainers: Ameri Holdings (NASDAQ: AMRH ) +152% . More news on: Ameri Holdings, Inc., Westwater Resources, Inc., Genius Brands International, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NASDAQ Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery an...
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...